Evercrisp Biosciences
Developer of a platform for tissue-targeted delivery of genetic therapies using machine learning–designed miniproteins. The platform focuses on receptor-mediated internalization and endosomal escape to deliver protein and oligonucleotide payloads (including ribonucleoproteins) into previously inaccessible tissues without relying on viral vectors or lipid nanoparticles. The company describes capabilities spanning computational protein design, bioconjugation, in vivo/translational studies, and scalable manufacturing.
Industries
Nr. of Employees
small (1-50)
Evercrisp Biosciences
Berkeley, California, United States, North America
Products
Tissue-targeted miniprotein delivery platform
A delivery platform based on designed miniproteins that mediate receptor binding, active cellular internalization, and endosomal escape to deliver protein and oligonucleotide therapeutics systemically without viral vectors or lipid nanoparticles.
Tissue-targeted miniprotein delivery platform
A delivery platform based on designed miniproteins that mediate receptor binding, active cellular internalization, and endosomal escape to deliver protein and oligonucleotide therapeutics systemically without viral vectors or lipid nanoparticles.
Services
Collaborative preclinical development and partnering
Partnerships to apply the miniprotein delivery platform in preclinical development, including lead optimization, in vivo proof-of-concept, and IND-enabling studies.
Collaborative preclinical development and partnering
Partnerships to apply the miniprotein delivery platform in preclinical development, including lead optimization, in vivo proof-of-concept, and IND-enabling studies.
Expertise Areas
- Targeted delivery of oligonucleotides and protein payloads
- Protein design and engineering
- Bioconjugation chemistry
- Computational biology and machine learning for protein design
Key Technologies
- Machine learning-driven protein design
- Receptor-mediated delivery
- Endosomal escape elements
- Ribonucleoprotein (RNP) delivery